LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Key to TGF-Beta Growth Stimulation Found

By Biotechdaily staff writers
Posted on 23 Dec 2003
Researchers have identified a group of proteins that when present inhibit the activity of transforming growth factor-beta (TGF-b) and prevent cell transformation.

TGF-b is known to function as both a growth stimulator and growth suppressor. To explain this apparent paradox, researchers at Vanderbilt University (Nashville, TN, USA; www.vanderbilt.edu) genetically engineered a line of cells lacking the TGF-b signaling proteins Rho-ROCK. They found that these cells, which derived from a line normally not affected by TGF-b, were readily transformed by the growth factor. Addition of extraneous Rho-Rock proteins restored the inhibition to TGF-b growth stimulation. These findings were published in the December 1, 2003, online edition of the Proceedings of the [U.S.] National Academy of Sciences.

"TGF-b usually causes cell growth inhibition; however, many solid tumors overexpress TGF-b and the cells are not inhibited at all--in fact, sometimes they grow faster than normal as a result of TGF-b signaling,” explained first author Dr. Neil A. Bhowmick, assistant professor of urologic surgery at Vanderbilt University. "Perhaps inactivation of this pathway is a way that cancer cells override the normal growth-suppressing activity of TGF-b.”




Related Links:
Vanderbilt University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
Alzheimer's Disease Biomarker Assay
Elecsys Phospho-Tau (217P) Plasma
New
Silver Member
Connectivity Solution
EKF Link

Latest BioResearch News

Genetic Study Links Inherited Blindness to Gene Tied to Rare Metabolic Disorder
23 Dec 2003  |   BioResearch

Population-Scale Proteomics Study Identifies New Genetic-Protein Links
23 Dec 2003  |   BioResearch

Circulating Tumor DNA Helps Identify Targets for Personalized Immunotherapy
23 Dec 2003  |   BioResearch